Navi Mumbai-based Inventurus Knowledge Solutions, commonly known as IKS Health, is a technology-enabled healthcare solutions provider founded in 2006. The company operates a care enablement platform that supports US-based healthcare organizations with operational, clinical and administrative tasks.
IKS Health has a market capitalization of around ₹24,552.12 crore, and its shares have declined close to 3% over the past year.
Watch the full conversation here
“We think there’s about a half a billion-dollar opportunity in their balance 500 hospitals to be able to install our system of action there,” Gupta said, outlining the core growth driver from the deal.
The acquisition gives IKS access to TrueBridge’s base of around 700 US hospitals, of which only about 200 currently use its revenue cycle system. Gupta said the company plans to integrate its own platform and cross-sell solutions across the remaining hospitals to unlock growth.
“The first vector of growth will be the cross-sell of the RCM system of action to their electronic health record (EHR) install base,” he said, adding that integration of IKS’ execution model will be key to scaling revenues.
Also Read:
Dr Reddy’s gains may be short-lived; Cipla, Sun Pharma face risks: Vishal Manchanda
While growth visibility is strong, margins are expected to dip initially before improving. “Margins will drop to about 26% pro forma at the close of this deal,” Gupta said, but added that the company has a track record of restoring profitability.
He expects a recovery over the medium term. “We feel confident about bringing the margins back to the early to mid-30s,” Gupta said, with a timeline of “18 to 24 months” for that transition.
Despite the near-term margin impact, the deal is expected to add to earnings from the start. “From the date of close, the deal is EPS accretive,” he said, after factoring in interest costs and amortization.
IKS is funding the acquisition largely through debt, which will increase leverage in the near term. “We’re taking on $557 million of additional debt… broadly it will be about $600 million of gross debt,” Gupta said.
However, he laid out a clear deleveraging roadmap alongside growth targets. “We’ve given ourselves a true north goal of ₹3000 crore of EBITDA and back to ₹300 crore of net debt by 2029-30 (FY30),” he said, indicating strong confidence in cash flow generation.
On currency risk, Gupta said the company’s dollar-linked revenues provide a natural hedge. “Our revenues are in dollars… the rupee depreciation helps us on the margin side as well,” he noted.
Catch all the latest updates from the stock market here
